1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > REGULATORY
REGULATORY
- MHLW Council OKs Public Knowledge-Based Applications for 3 Drugs Including Acetaminophen
June 9, 2022
- 60% in Japan Get Three COVID Shots, Nearly 90% for Older Adults: Govt
June 9, 2022
- Edurant Label Revised for Combined Use with Vocabria
June 8, 2022
- Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
June 8, 2022
- AMED Sets to Lay R&D Data Utilization Infrastructure from Current Fiscal Year
June 8, 2022
- Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
- Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
- Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
- Japan Govt to Set Biosimilar Target by March 2023: Honebuto Draft
June 6, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
- MHLW Panel Endorses Sanofi’s Sutimlimab as Japan’s First CAD Therapy
June 3, 2022
- LDP Pharma Study Group Prods Rethink of Annual Re-Pricing, but Health Minister Sounds Negative
June 3, 2022
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
June 3, 2022
- Working Group Urges Govt to Discuss Use of Anonymized Medical Data for Regulatory Purposes
June 2, 2022
- Panel OKs Orphan Designation for Pfizer’s Hemophilia Gene Therapy
June 2, 2022
- Honebuto Draft Fails to Clear LDP, Renewed Discussions Set for June 3
June 2, 2022
- Govt’s Draft Grand Design for New Capitalism Vows to Spur Biotechnology Innovation
June 1, 2022
- Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
- ViiV’s Vocabria, Janssen’s Rekambys for HIV to Join NHI Price List on June 8
June 1, 2022
- Post-Launch Safety Steps to Be More Important with Emergency Approval: Official
May 31, 2022
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…